UAB Research Finds Obesity Drug Can Reduce the Risk of Type 2 Diabetes

New research conducted by the University of Alabama at Birmingham (UAB) has discovered that an obesity drug can reduce the risk of Type 2 diabetes by 60%. The drug, which has been approved by the Food and Drug Administration at a dose of one milligram weekly, shows that a higher dose of 2.4 milligrams could be more effective in weight loss, thereby reducing the risk of Type 2 diabetes.

Dr. Jessica Schmitt, Assistant Professor in the Division of Pediatric Endocrinology and Diabetes at UAB and Children’s, emphasized the strong link between obesity and the progression to Type 2 diabetes. Alabama, in particular, has seen a significant rise in diabetes cases post-pandemic, with the state experiencing a much higher rate of Type 2 diabetes compared to other parts of the country.

Semaglutide, the drug in question, has been shown to reduce weight by over 15 percent on average when used in conjunction with a healthy lifestyle. Dr. Schmitt explained that Semaglutide works by slowing down how quickly the stomach empties, making people feel full longer, and by increasing the body's ability to release its own insulin, thereby helping to regulate blood sugars more effectively.

The rise in obesity rates nationwide, attributed to a sedentary lifestyle, has led to an increase in the prevalence of Type 2 Diabetes. This research underscores the potential of Semaglutide in addressing both obesity and diabetes, particularly in regions like Alabama where the need is greatest.